HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen.

AbstractOBJECTIVES:
Progestogen-only pills (POPs) are safer with respect to cardiovascular risks than contraceptives containing estrogens. Despite the increased contraceptive efficacy of a desogestrel-only pill compared with a traditional POP, POPs are still not widely used due to an unpredictable bleeding pattern. A new POP containing 4 mg drospirenone has been developed with a 24/4 intake regimen which may improve the bleeding pattern. The objectives of this study were to investigate ovulation inhibition with the new drospirenone-only pill in comparison with the desogestrel-only pill and, in addition, to assess the effects on cervical mucus permeability and bleeding.
METHODS:
Sixty-four healthy volunteers with proven ovulatory cycles were randomised and treated with either the drospirenone-only or the desogestrel-only pill during two 28-day cycles. Follicular diameter, endometrial thickness, and serum estradiol (E2) and progesterone concentrations were measured and Hoogland scores were determined. Additionally, cervical mucus scores, bleeding and return of ovulation were assessed.
RESULTS:
Both treatments effectively inhibited ovulation. Follicular diameter, E2 levels and Hoogland scores were equal, demonstrating efficient ovarian suppression. One subject in each group had a Hoogland score of 6, but the criteria for normal luteal activity were not fulfilled. In both groups, ovulation did not occur before day 9 of the post-treatment cycle. Cervical mucus permeability was suppressed in both groups. The median number of bleeding and spotting days was lower in the drospirenone group.
CONCLUSIONS:
The new drospirenone-only pill inhibited ovulation as effectively as the desogestrel-only pill despite the 4-day hormone-free interval.
AuthorsIngrid J M Duijkers, Doris Heger-Mahn, Dominique Drouin, Sven Skouby
JournalThe European journal of contraception & reproductive health care : the official journal of the European Society of Contraception (Eur J Contracept Reprod Health Care) Vol. 20 Issue 6 Pg. 419-27 ( 2015) ISSN: 1473-0782 [Electronic] England
PMID26073333 (Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Androstenes
  • Contraceptives, Oral, Synthetic
  • Progesterone
  • Estradiol
  • Desogestrel
  • drospirenone
Topics
  • Adult
  • Androstenes (chemistry, pharmacology)
  • Cervix Mucus (drug effects, metabolism)
  • Contraceptives, Oral, Synthetic (chemistry, pharmacology)
  • Desogestrel (chemistry, pharmacology)
  • Endometrium (anatomy & histology, drug effects)
  • Estradiol (blood)
  • Female
  • Healthy Volunteers
  • Humans
  • Metrorrhagia (chemically induced)
  • Ovarian Follicle (anatomy & histology, drug effects)
  • Ovulation Inhibition (drug effects)
  • Permeability (drug effects)
  • Progesterone (blood)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: